Q4 FY22 Earnings Presentation

Portfolio summary Cardiovascular Coronary & Peripheral Vascular $603M -0.3% Y/Y Rep +1.3% Y/Y Org <... $2,745M +1.4% Y/Y Rep Structural Heart +3.4% Y/Y Org & Aortic $740M +1.4% Y/Y Rep +3.7% Y/Y Org Table of Executive Portfolio Financial Guidance & Contents Summary Highlights Highlights Assumptions Cardiac Rhythm & Heart Failure $1,402M +2.3% Y/Y Rep +4.2% Y/Y Org +6.9% ex-MCS Y/Y Org Neuromodulation $409M -4.0% Y/Y Rep -2.8% Y/Y Org ..... Specialty Therapies $633M +2.4% Y/Y Rep +3.1% Y/Y Org Medical Surgical Neuroscience $2,144M +0.8% Y/Y Rep +1.8% Y/Y Org ☑ Diabetes Respiratory, Gastrointestinal & Renal $771M -13.4% Y/Y Rep -11.6% Y/Y Org +0.2% ex-Vents Y/Y Org $2,290M -1.0% Y/Y Rep +1.2% Y/Y Org +6.2% ex-Vents Y/Y Org Surgical Innovations $1,519M +6.7% Y/Y Rep +9.2% Y/Y Org Revenue has been intentionally rounded to the nearest million and, therefore, may not sum. 8 Q3 FY22 earnings presentation | February 22, 2022 $584M -7.3% Y/Y Rep -5.4% Y/Y Org ESG Appendix Cranial & Spinal Technologies $1,102M +1.9% Y/Y Rep +3.1% Y/Y Org Medtronic

View entire presentation